tiprankstipranks
Advertisement
Advertisement

SLDB Stock Latest News

Solid Biosciences Shareholders Approve Directors and Share Increase
Company AnnouncementsSolid Biosciences Shareholders Approve Directors and Share Increase
12d ago
8K
SLDB
Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright
PremiumThe Fly
Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright
20d ago
SLDB
Solid Biosciences price target lowered to $16 from $17 at Wedbush
PremiumThe Fly
Solid Biosciences price target lowered to $16 from $17 at Wedbush
1M ago
SLDB
Solid Biosciences price target raised to $18 from $17 at Piper Sandler
PremiumThe Fly
Solid Biosciences price target raised to $18 from $17 at Piper Sandler
1M ago
SLDB
Solid Biosciences doses part participant in IMPACT DUCHENNE study
PremiumThe Fly
Solid Biosciences doses part participant in IMPACT DUCHENNE study
2M ago
SLDB
Solid Biosciences receives orphan drug designation for SGT-003 from EC
PremiumThe FlySolid Biosciences receives orphan drug designation for SGT-003 from EC
2M ago
SLDB
Solid Biosciences Adjusts Board Classes in Governance Move
Premium
Company Announcements
Solid Biosciences Adjusts Board Classes in Governance Move
2M ago
8K
SLDB
Solid Biosciences price target raised to $12 from $11 at JPMorgan
Premium
The Fly
Solid Biosciences price target raised to $12 from $11 at JPMorgan
3M ago
SLDB
3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
3M ago
COYA
CTMX
Solid Biosciences: Strong SGT-003 Clinical Profile, Emerging Pipeline, and Robust Cash Runway Underpin Buy Rating
PremiumRatings
Solid Biosciences: Strong SGT-003 Clinical Profile, Emerging Pipeline, and Robust Cash Runway Underpin Buy Rating
3M ago
SLDB
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows
PremiumCompany Announcements
Evolving Tax Rules and New Excise Levies Threaten Solid Biosciences’ Profitability and Cash Flows
3M ago
SLDB
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
PremiumThe Fly
Guggenheim starts Solid Biosciences with a Buy on DMD gene therapy potential
3M ago
SLDB
SRPT
Solid Biosciences initiated with a Buy at Guggenheim
PremiumThe FlySolid Biosciences initiated with a Buy at Guggenheim
3M ago
SLDB
Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target
Premium
Ratings
Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target
3M ago
SLDB
Solid Biosciences files to sell 1.32M shares of common stock for holders
Premium
The Fly
Solid Biosciences files to sell 1.32M shares of common stock for holders
3M ago
SLDB
Solid Biosciences files to sell 42.78M shares of common stock for holders
PremiumThe Fly
Solid Biosciences files to sell 42.78M shares of common stock for holders
3M ago
SLDB
Solid Biosciences reports Q4 EPS (53c), consensus (52c)
PremiumThe Fly
Solid Biosciences reports Q4 EPS (53c), consensus (52c)
3M ago
SLDB
Buy Rating on SGT-003 Driven by Best-in-Class Efficacy Signals, Improving Safety, and Accelerated Approval Optionality
PremiumRatings
Buy Rating on SGT-003 Driven by Best-in-Class Efficacy Signals, Improving Safety, and Accelerated Approval Optionality
3M ago
SLDB
SLDB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
SLDB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
SLDB
Solid Biosciences price target raised to $17 from $14 at Wedbush
PremiumThe FlySolid Biosciences price target raised to $17 from $14 at Wedbush
3M ago
SLDB
Solid Biosciences: INSPIRE DUCHENNE Data and FDA Pathway Support Overweight/Buy Rating on SGT-003 Gene Therapy Upside
Premium
Ratings
Solid Biosciences: INSPIRE DUCHENNE Data and FDA Pathway Support Overweight/Buy Rating on SGT-003 Gene Therapy Upside
3M ago
SLDB
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data
Premium
Company Announcements
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data
3M ago
8K
SLDB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >